Fremanezumab for the Treatment of Migraine Complicated by Medication Overuse: A Systematic Review

被引:0
作者
Hajjaj, Ibrahim [1 ]
Baraldi, Carlo [2 ]
Pellesi, Lanfranco [1 ]
机构
[1] Univ Southern Denmark, Dept Publ Hlth, Clin Pharmacol Pharm & Environm Med, Campusvej 55, DK-5230 Odense, Denmark
[2] Azienda Unita Sanit Locale Modena, Modena, Italy
关键词
HEADACHE;
D O I
10.1007/s40261-025-01433-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, such as fremanezumab, are effective for migraine prevention. However, their effectiveness in treating migraine complicated by medication overuse, remains underexplored. Objective This systematic review aims to evaluate the effectiveness of fremanezumab in adults with migraine complicated by medication overuse. Methods We systematically searched PubMed and Embase (Ovid) databases for studies on fremanezumab, selecting primary studies that included adults with migraine complicated by medication overuse and reported at least one efficacy outcome. The search was performed in January 2024 and then updated in June 2024. Risk of bias for randomized controlled trials was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool, while real-world studies were evaluated using both the ROBINS-I and ROB-ME tools. Data extraction and analysis followed established guidelines. Results Our search identified 176 records, of which 2 clinical trials and 7 real-world studies were included. Included studies recruited a total of 1422 adults with migraine complicated by medication overuse. In post hoc analyses from clinical trials, fremanezumab significantly reduced monthly migraine days, days with acute headache medication use, and Headache Impact Test (HIT-6) scores compared to placebo during a 12-week period. The real-world studies reported a reduction in monthly headache days at 6 months, and a high reversion rate from medication overuse headache (MOH) after one year of treatment. Conclusion Both post hoc analyses from clinical trials and real-world studies support fremanezumab benefits in reducing migraine frequency, medication use, and headache-related disability in adults with migraine complicated by medication overuse. Given the limited quality of data, further real-world research with standardized reporting criteria is needed to substantiate long-term benefits and establish optimal treatment protocols.
引用
收藏
页码:247 / 254
页数:8
相关论文
共 27 条
  • [1] Medication overuse headache
    Ashina, Sait
    Terwindt, Gisela M. M.
    Steiner, Timothy J. J.
    Lee, Mi Ji
    Porreca, Frank
    Tassorelli, Cristina
    Schwedt, Todd J. J.
    Jensen, Rigmor H. H.
    Diener, Hans-Christoph
    Lipton, Richard B. B.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2023, 9 (01)
  • [2] Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
    Barbanti, Piero
    Egeo, Gabriella
    Proietti, Stefania
    d'Onofrio, Florindo
    Aurilia, Cinzia
    Finocchi, Cinzia
    Di Clemente, Laura
    Zucco, Maurizio
    Doretti, Alberto
    Messina, Stefano
    Autunno, Massimo
    Ranieri, Angelo
    Carnevale, Antonio
    Colombo, Bruno
    Filippi, Massimo
    Tasillo, Miriam
    Rinalduzzi, Steno
    Querzani, Pietro
    Sette, Giuliano
    Forino, Lorenzo
    Zoroddu, Francesco
    Robotti, Micaela
    Valenza, Alessandro
    Camarda, Cecilia
    Borrello, Laura
    Aguggia, Marco
    Viticchi, Giovanna
    Tomino, Carlo
    Fiorentini, Giulia
    Orlando, Bianca
    Bonassi, Stefano
    Torelli, Paola
    [J]. NEUROLOGY AND THERAPY, 2024, 13 (03) : 611 - 624
  • [3] Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study
    Caponnetto, Valeria
    Russo, Antonio
    Silvestro, Marcello
    Tessitore, Alessandro
    De Icco, Roberto
    Vaghi, Gloria
    Sances, Grazia
    Tassorelli, Cristina
    Baraldi, Carlo
    Lo Castro, Flavia
    Guerzoni, Simona
    Prudenzano, Maria Pia
    Fallacara, Adriana
    Gentile, Martino
    Ornello, Raffaele
    Onofri, Agnese
    Burgalassi, Andrea
    Chiarugi, Alberto
    De Cesaris, Francesco
    Granato, Antonio
    Casalena, Alfonsina
    De Tommaso, Marina
    Mampreso, Edoardo
    Merlo, Paola
    Coppola, Gianluca
    Battistini, Stefania
    Rebecchi, Valentina
    Rainero, Innocenzo
    Sepe, Federica Nicoletta
    Dalla Volta, Giorgio
    Sacco, Simona
    Geppetti, Pierangelo
    Iannone, Luigi Francesco
    [J]. CNS DRUGS, 2023, 37 (12) : 1069 - 1080
  • [4] Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update
    Charles, Andrew C.
    Digre, Kathleen B.
    Goadsby, Peter J.
    Robbins, Matthew S.
    Hershey, Andrew
    [J]. HEADACHE, 2024, 64 (04): : 333 - 341
  • [5] Medication Overuse and Medication Overuse Headache: Risk Factors, Comorbidities, Associated Burdens and Nonpharmacologic and Pharmacologic Treatment Approaches
    Chen, Ping-Kun
    Wang, Shuu-Jiun
    [J]. CURRENT PAIN AND HEADACHE REPORTS, 2019, 23 (08)
  • [6] Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial
    Dodick, David W.
    Silberstein, Stephen D.
    Bigal, Marcelo E.
    Yeung, Paul P.
    Goadsby, Peter J.
    Blankenbiller, Tricia
    Grozinski-Wolff, Melissa
    Yang, Ronghua
    Ma, Yuju
    Aycardi, Ernesto
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (19): : 1999 - 2008
  • [7] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
    Driessen, Maurice T.
    Cohen, Joshua M.
    Thompson, Stephen F.
    Patterson-Lomba, Oscar
    Seminerio, Michael J.
    Carr, Karen
    Totev, Todor, I
    Sun, Rochelle
    Yim, Erica
    Mu, Fan
    Ayyagari, Rajeev
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01)
  • [8] Polypharmacy Among Headache Patients: A Cross-Sectional Study
    Ferrari, Anna
    Baraldi, Carlo
    Licata, Manuela
    Rustichelli, Cecilia
    [J]. CNS DRUGS, 2018, 32 (06) : 567 - 578
  • [9] Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
    Ferrari, Michel D.
    Diener, Hans Christoph
    Ning, Xiaoping
    Galic, Maja
    Cohen, Joshua M.
    Yang, Ronghua
    Mueller, Matthias
    Ahn, Andrew H.
    Schwartz, Yael Carmeli
    Grozinski-Wolff, Melissa
    Janka, Lindsay
    Ashina, Messoud
    [J]. LANCET, 2019, 394 (10203) : 1030 - 1040
  • [10] Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
    Imai, Noboru
    Isogai, Yuki
    Shibasaki, Yoshiyuki
    Nakai, Masami
    Ishida, Miki
    Ning, Xiaoping
    Koga, Nobuyuki
    [J]. NEUROLOGY AND THERAPY, 2023, 12 (06) : 1981 - 1991